← Leaderboards
Lance David Miller
Wake Forest University Health Sciences
$2,718,111
Attributed
$4,934,610
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1M · FY2019–25$2M$1.5M$1M$500K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,934,610 · 3
By mechanism
R01$4,432,998 · 2
P30$501,612 · 1
Top collaborators
- Konstantinos Votanopoulos9 shared
Most similar at Wake Forest University Health Sciences
Same institution · by research overlap
- Konstantinos Votanopoulos$2,216,499
Others in their field
Other Emerging Leaders on “Malignant Neoplasms”
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
- Leonard Freedmand · Leidos Biomedical Research, Inc.$108,968,336
- Beverly Hayes · Leidos Biomedical Research, Inc.$98,336,166
- Martha Hering · Westat, Inc.$57,098,843
Research focus
Malignant NeoplasmsGenomicsTranslatingInstitutionPersonalized MedicineGeneticMolecularMalignant Neoplasm Of AppendixGenotypeMalignant Neoplasm Of Gastrointestinal TractExhibitsDrug SensitivityAnatomyIntraperitoneal TherapyGene MutationDna Sequence AlterationChemoresistanceDrug ResistanceColon CarcinomaCancer PatientDrug TestingBiopsyChemotherapyCharacteristics
Grant awards (17)
Tumor Organoid-Mediated Drug Testing and Clonality Analysis in Peritoneal Surface Disease of Intestinal Origin$494,107
R01 · FY2025 · CA
Establishing the Repertoire of Actionable Alterations in Appendiceal Adenocarcinoma$477,793
R01 · FY2025 · CA · contact PI
Tumor Organoid-Mediated Drug Testing and Clonality Analysis in Peritoneal Surface Disease of Intestinal Origin$478,598
R01 · FY2024 · CA
Establishing the Repertoire of Actionable Alterations in Appendiceal Adenocarcinoma$473,282
R01 · FY2024 · CA · contact PI
Establishing the Repertoire of Actionable Alterations in Appendiceal Adenocarcinoma$505,425
R01 · FY2023 · CA · contact PI
Tumor Organoid-Mediated Drug Testing and Clonality Analysis in Peritoneal Surface Disease of Intestinal Origin$494,277
R01 · FY2023 · CA
Establishing the Repertoire of Actionable Alterations in Appendiceal Adenocarcinoma$513,418
R01 · FY2022 · CA · contact PI
Tumor Organoid-Mediated Drug Testing and Clonality Analysis in Peritoneal Surface Disease of Intestinal Origin$494,928
R01 · FY2022 · CA
Tumor Organoid-Mediated Drug Testing and Clonality Analysis in Peritoneal Surface Disease of Intestinal Origin$501,170
R01 · FY2021 · CA
Cancer Genomics Shared Resource$125,927
P30 · FY2021 · CA · contact PI
Cancer Genomics Shared Resource$125,209
P30 · FY2020 · CA · contact PI
Cancer Genomics Shared Resource$185,574
P30 · FY2019 · CA · contact PI
Cancer Genomics Shared Resource$29,411
P30 · FY2019 · CA · contact PI
Cancer Genomics Shared Resource$14,690
P30 · FY2019 · CA · contact PI
Cancer Genomics Shared Resource$11,764
P30 · FY2019 · CA · contact PI
Cancer Genomics Shared Resource$5,639
P30 · FY2019 · CA · contact PI
Cancer Genomics Shared Resource$3,398
P30 · FY2019 · CA · contact PI